• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.08% Nasdaq Up0.22%

    StemCells Inc. (STEM)

    0.54 Up 0.00(0.39%) Nov 27, 12:59PM EST
    ProfileGet Profile for:
    StemCells Inc.
    7707 Gateway Boulevard
    Suite 140
    Newark, CA 94560
    United States - Map
    Phone: 510-456-4000
    Fax: 510-456-4001
    Website: http://www.stemcellsinc.com

    Index Membership:N/A
    Full Time Employees:69

    Business Summary 

    StemCells, Inc., a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development. It engages in clinical development of its platform technology, HuCNS-SC, a purified human neural stem cells used as a potential treatment for disorders of the central nervous system. The company has completed Phase I/II clinical trial for the treatment of chronic spinal cord injury; and Phase I clinical trial for the treatment of Pelizaeus-Merzbacher disease, as well as completed enrollment and treatment in its Phase I/II clinical trial in geographic atrophy of age-related macular degeneration that cause blindness in the elderly. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on StemCells Inc.

    Key Executives 
    Mr. Martin M. McGlynn , 69
    Chief Exec. Officer, Director, Member of Strategic Transactions Committee, Chief Exec. Officer of Stemcells California Inc and Pres of Stemcells California Inc
    Mr. Gregory T. Schiffman MBA, CPA, 58
    Chief Financial Officer and Exec. VP of Fin.
    Mr. Kenneth B. Stratton J.D., Esq., 46
    Gen. Counsel and Sec.
    Dr. Ian John Massey D.Phil, 64
    Pres and Chief Operating Officer
    Dr. Ann Tsukamoto Ph.D., 62
    Exec. VP of Scientific & Strategic Alliances
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders